http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 19 May 2026 09:01:13 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/NEXGEL+hydrogel+patch+reduces+laser+plume+by+95.6%25+in+hair+removal+study/26518427.html <p>NEXGEL Inc. (NASDAQ: NXGL) reported results from a clinical study showing its hydrogel patch reduced laser plume concentration by 95.6% during laser hair removal procedures compared to a control group.</p><p>The randomized, single-center study involved 30 patients and was conducted at the Florida Clinical Research Center by plastic surgeons Dr. Barry DiBernardo and Dr. Jason Pozner. The study was funded by Innovative Optics, a supplier of safety products for healthcare facilities.</p><p>The intervention site demonstrated a 37.2% mean reduction in hair density at 90 days post-treatment versus 26.7% on the control side. Mean pain scores were lower on the intervention side at http://www.streetinsider.com/Corporate+News/NEXGEL+hydrogel+patch+reduces+laser+plume+by+95.6%25+in+hair+removal+study/26518427.html Tue, 19 May 2026 09:01:13 -0400 NXGL NXGLW http://www.streetinsider.com/Corporate+News/NEXGEL+hydrogel+patch+reduces+laser+plume+by+95.6%25+in+hair+removal+study/26518427.html <p>NEXGEL Inc. (NASDAQ: NXGL) reported results from a clinical study showing its hydrogel patch reduced laser plume concentration by 95.6% during laser hair removal procedures compared to a control group.</p><p>The randomized, single-center study involved 30 patients and was conducted at the Florida Clinical Research Center by plastic surgeons Dr. Barry DiBernardo and Dr. Jason Pozner. The study was funded by Innovative Optics, a supplier of safety products for healthcare facilities.</p><p>The intervention site demonstrated a 37.2% mean reduction in hair density at 90 days post-treatment versus 26.7% on the control side. Mean pain scores were lower on the intervention side at http://www.streetinsider.com/Corporate+News/NEXGEL+hydrogel+patch+reduces+laser+plume+by+95.6%25+in+hair+removal+study/26518427.html Tue, 19 May 2026 09:01:13 -0400 NXGL NXGLW http://www.streetinsider.com/FDA/NEXGEL+hydrogel+patch+reduces+laser+plume+by+95.6%25+in+hair+removal+study/26518427.html <p>NEXGEL Inc. (NASDAQ: NXGL) reported results from a clinical study showing its hydrogel patch reduced laser plume concentration by 95.6% during laser hair removal procedures compared to a control group.</p><p>The randomized, single-center study involved 30 patients and was conducted at the Florida Clinical Research Center by plastic surgeons Dr. Barry DiBernardo and Dr. Jason Pozner. The study was funded by Innovative Optics, a supplier of safety products for healthcare facilities.</p><p>The intervention site demonstrated a 37.2% mean reduction in hair density at 90 days post-treatment versus 26.7% on the control side. Mean pain scores were lower on the intervention side at http://www.streetinsider.com/FDA/NEXGEL+hydrogel+patch+reduces+laser+plume+by+95.6%25+in+hair+removal+study/26518427.html Tue, 19 May 2026 09:01:13 -0400 NXGL NXGLW http://www.streetinsider.com/FDA/NEXGEL+hydrogel+patch+reduces+laser+plume+by+95.6%25+in+hair+removal+study/26518427.html <p>NEXGEL Inc. (NASDAQ: NXGL) reported results from a clinical study showing its hydrogel patch reduced laser plume concentration by 95.6% during laser hair removal procedures compared to a control group.</p><p>The randomized, single-center study involved 30 patients and was conducted at the Florida Clinical Research Center by plastic surgeons Dr. Barry DiBernardo and Dr. Jason Pozner. The study was funded by Innovative Optics, a supplier of safety products for healthcare facilities.</p><p>The intervention site demonstrated a 37.2% mean reduction in hair density at 90 days post-treatment versus 26.7% on the control side. Mean pain scores were lower on the intervention side at http://www.streetinsider.com/FDA/NEXGEL+hydrogel+patch+reduces+laser+plume+by+95.6%25+in+hair+removal+study/26518427.html Tue, 19 May 2026 09:01:13 -0400 NXGL NXGLW http://www.streetinsider.com/Press+Releases/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html <p align="center"><i>The study concluded that NEXGEL’s hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to the control</i></p> <p align="center"><i>The study was published in Lasers in Surgery and Medicine, 2026</i></p> <p align="justify"><b>LANGHORNE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- </b>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced positive data from the randomized, 30-patient, single-center Institutional Review Board (IRB) clinical http://www.streetinsider.com/Press+Releases/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html Tue, 19 May 2026 09:00:00 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Press+Releases/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html <p align="center"><i>The study concluded that NEXGEL’s hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to the control</i></p> <p align="center"><i>The study was published in Lasers in Surgery and Medicine, 2026</i></p> <p align="justify"><b>LANGHORNE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- </b>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced positive data from the randomized, 30-patient, single-center Institutional Review Board (IRB) clinical http://www.streetinsider.com/Press+Releases/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html Tue, 19 May 2026 09:00:00 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Press+Releases/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html <p align="center"><i>The study concluded that NEXGEL’s hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to the control</i></p> <p align="center"><i>The study was published in Lasers in Surgery and Medicine, 2026</i></p> <p align="justify"><b>LANGHORNE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- </b>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced positive data from the randomized, 30-patient, single-center Institutional Review Board (IRB) clinical http://www.streetinsider.com/Press+Releases/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html Tue, 19 May 2026 09:00:00 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Press+Releases/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html <p align="center"><i>The study concluded that NEXGEL’s hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to the control</i></p> <p align="center"><i>The study was published in Lasers in Surgery and Medicine, 2026</i></p> <p align="justify"><b>LANGHORNE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- </b>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced positive data from the randomized, 30-patient, single-center Institutional Review Board (IRB) clinical http://www.streetinsider.com/Press+Releases/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html Tue, 19 May 2026 09:00:00 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Press+Releases/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html <p align="center"><i>The study concluded that NEXGEL’s hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to the control</i></p> <p align="center"><i>The study was published in Lasers in Surgery and Medicine, 2026</i></p> <p align="justify"><b>LANGHORNE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- </b>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced positive data from the randomized, 30-patient, single-center Institutional Review Board (IRB) clinical http://www.streetinsider.com/Press+Releases/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html Tue, 19 May 2026 09:00:00 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Globe+Newswire/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html <p align="center"><i>The study concluded that NEXGEL’s hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to the control</i></p> <p align="center"><i>The study was published in Lasers in Surgery and Medicine, 2026</i></p> <p align="justify"><b>LANGHORNE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- </b>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced positive data from the randomized, 30-patient, single-center Institutional Review Board (IRB) clinical http://www.streetinsider.com/Globe+Newswire/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html Tue, 19 May 2026 09:00:00 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Globe+Newswire/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html <p align="center"><i>The study concluded that NEXGEL’s hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to the control</i></p> <p align="center"><i>The study was published in Lasers in Surgery and Medicine, 2026</i></p> <p align="justify"><b>LANGHORNE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- </b>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced positive data from the randomized, 30-patient, single-center Institutional Review Board (IRB) clinical http://www.streetinsider.com/Globe+Newswire/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html Tue, 19 May 2026 09:00:00 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Globe+Newswire/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html <p align="center"><i>The study concluded that NEXGEL’s hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to the control</i></p> <p align="center"><i>The study was published in Lasers in Surgery and Medicine, 2026</i></p> <p align="justify"><b>LANGHORNE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- </b>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced positive data from the randomized, 30-patient, single-center Institutional Review Board (IRB) clinical http://www.streetinsider.com/Globe+Newswire/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html Tue, 19 May 2026 09:00:00 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Globe+Newswire/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html <p align="center"><i>The study concluded that NEXGEL’s hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to the control</i></p> <p align="center"><i>The study was published in Lasers in Surgery and Medicine, 2026</i></p> <p align="justify"><b>LANGHORNE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- </b>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced positive data from the randomized, 30-patient, single-center Institutional Review Board (IRB) clinical http://www.streetinsider.com/Globe+Newswire/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html Tue, 19 May 2026 09:00:00 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Globe+Newswire/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html <p align="center"><i>The study concluded that NEXGEL’s hydrogel patch significantly reduced laser plume generation and exposure during laser hair removal and the patch was associated with greater hair reduction and reduced pain compared to the control</i></p> <p align="center"><i>The study was published in Lasers in Surgery and Medicine, 2026</i></p> <p align="justify"><b>LANGHORNE, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- </b>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced positive data from the randomized, 30-patient, single-center Institutional Review Board (IRB) clinical http://www.streetinsider.com/Globe+Newswire/NEXGEL+Reports+Positive+Data+from+Randomized+Single-Center+IRB+Study+to+Evaluate+the+Effectiveness+and+Safety+of+a+Hydrogel+Laser+Treatment+Patch+in+Laser+Hair+Removal+with+a+95.6%25+Reduction+in+Plume+/26518259.html Tue, 19 May 2026 09:00:00 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Management+Changes/NEXGEL+names+Dave+Hazard+VP+of+sales+for+BIONX+Surgical+division/26482352.html <p>NEXGEL, Inc. (NASDAQ: NXGL) appointed Dave Hazard as Vice President of Sales for its BIONX Surgical division, according to a company statement. The appointment supports the commercialization of the newly launched surgical division.</p> <p>Hazard brings more than 13 years of sales leadership experience across orthopedics, spine, and biologics sectors. He most recently served at Nuo Therapeutics, Inc. for four years, where he commercialized Aurix wound care PRP products and built a salesforce of more than 400 representatives. During his tenure, he secured Smith+Nephew as a white label partner for the Centrio product line.</p> <p>Prior to Nuo Therapeutics, Hazard worked as Regional Manager http://www.streetinsider.com/Management+Changes/NEXGEL+names+Dave+Hazard+VP+of+sales+for+BIONX+Surgical+division/26482352.html Wed, 13 May 2026 08:30:40 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Management+Changes/NEXGEL+names+Dave+Hazard+VP+of+sales+for+BIONX+Surgical+division/26482352.html <p>NEXGEL, Inc. (NASDAQ: NXGL) appointed Dave Hazard as Vice President of Sales for its BIONX Surgical division, according to a company statement. The appointment supports the commercialization of the newly launched surgical division.</p> <p>Hazard brings more than 13 years of sales leadership experience across orthopedics, spine, and biologics sectors. He most recently served at Nuo Therapeutics, Inc. for four years, where he commercialized Aurix wound care PRP products and built a salesforce of more than 400 representatives. During his tenure, he secured Smith+Nephew as a white label partner for the Centrio product line.</p> <p>Prior to Nuo Therapeutics, Hazard worked as Regional Manager http://www.streetinsider.com/Management+Changes/NEXGEL+names+Dave+Hazard+VP+of+sales+for+BIONX+Surgical+division/26482352.html Wed, 13 May 2026 08:30:40 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Management+Changes/NEXGEL+names+Dave+Hazard+VP+of+sales+for+BIONX+Surgical+division/26482352.html <p>NEXGEL, Inc. (NASDAQ: NXGL) appointed Dave Hazard as Vice President of Sales for its BIONX Surgical division, according to a company statement. The appointment supports the commercialization of the newly launched surgical division.</p> <p>Hazard brings more than 13 years of sales leadership experience across orthopedics, spine, and biologics sectors. He most recently served at Nuo Therapeutics, Inc. for four years, where he commercialized Aurix wound care PRP products and built a salesforce of more than 400 representatives. During his tenure, he secured Smith+Nephew as a white label partner for the Centrio product line.</p> <p>Prior to Nuo Therapeutics, Hazard worked as Regional Manager http://www.streetinsider.com/Management+Changes/NEXGEL+names+Dave+Hazard+VP+of+sales+for+BIONX+Surgical+division/26482352.html Wed, 13 May 2026 08:30:40 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Management+Changes/NEXGEL+names+Dave+Hazard+VP+of+sales+for+BIONX+Surgical+division/26482352.html <p>NEXGEL, Inc. (NASDAQ: NXGL) appointed Dave Hazard as Vice President of Sales for its BIONX Surgical division, according to a company statement. The appointment supports the commercialization of the newly launched surgical division.</p> <p>Hazard brings more than 13 years of sales leadership experience across orthopedics, spine, and biologics sectors. He most recently served at Nuo Therapeutics, Inc. for four years, where he commercialized Aurix wound care PRP products and built a salesforce of more than 400 representatives. During his tenure, he secured Smith+Nephew as a white label partner for the Centrio product line.</p> <p>Prior to Nuo Therapeutics, Hazard worked as Regional Manager http://www.streetinsider.com/Management+Changes/NEXGEL+names+Dave+Hazard+VP+of+sales+for+BIONX+Surgical+division/26482352.html Wed, 13 May 2026 08:30:40 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Management+Changes/NEXGEL+names+Dave+Hazard+VP+of+sales+for+BIONX+Surgical+division/26482352.html <p>NEXGEL, Inc. (NASDAQ: NXGL) appointed Dave Hazard as Vice President of Sales for its BIONX Surgical division, according to a company statement. The appointment supports the commercialization of the newly launched surgical division.</p> <p>Hazard brings more than 13 years of sales leadership experience across orthopedics, spine, and biologics sectors. He most recently served at Nuo Therapeutics, Inc. for four years, where he commercialized Aurix wound care PRP products and built a salesforce of more than 400 representatives. During his tenure, he secured Smith+Nephew as a white label partner for the Centrio product line.</p> <p>Prior to Nuo Therapeutics, Hazard worked as Regional Manager http://www.streetinsider.com/Management+Changes/NEXGEL+names+Dave+Hazard+VP+of+sales+for+BIONX+Surgical+division/26482352.html Wed, 13 May 2026 08:30:40 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Press+Releases/NEXGEL+Appoints+Dave+Hazard+as+Vice+President+of+Sales+for+BIONX+Surgical/26482335.html <p align="center"><i>Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue</i></p> <p align="justify"><b>LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- </b>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Dave Hazard as Vice President of Sales for BIONX Surgical, a division of NEXGEL. Mr. Hazard brings more than 13 years of sales leadership across orthopedics, spine, and biologics, and joins BIONX Surgical at a key http://www.streetinsider.com/Press+Releases/NEXGEL+Appoints+Dave+Hazard+as+Vice+President+of+Sales+for+BIONX+Surgical/26482335.html Wed, 13 May 2026 08:30:00 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Press+Releases/NEXGEL+Appoints+Dave+Hazard+as+Vice+President+of+Sales+for+BIONX+Surgical/26482335.html <p align="center"><i>Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue</i></p> <p align="justify"><b>LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- </b>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Dave Hazard as Vice President of Sales for BIONX Surgical, a division of NEXGEL. Mr. Hazard brings more than 13 years of sales leadership across orthopedics, spine, and biologics, and joins BIONX Surgical at a key http://www.streetinsider.com/Press+Releases/NEXGEL+Appoints+Dave+Hazard+as+Vice+President+of+Sales+for+BIONX+Surgical/26482335.html Wed, 13 May 2026 08:30:00 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Press+Releases/NEXGEL+Appoints+Dave+Hazard+as+Vice+President+of+Sales+for+BIONX+Surgical/26482335.html <p align="center"><i>Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue</i></p> <p align="justify"><b>LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- </b>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Dave Hazard as Vice President of Sales for BIONX Surgical, a division of NEXGEL. Mr. Hazard brings more than 13 years of sales leadership across orthopedics, spine, and biologics, and joins BIONX Surgical at a key http://www.streetinsider.com/Press+Releases/NEXGEL+Appoints+Dave+Hazard+as+Vice+President+of+Sales+for+BIONX+Surgical/26482335.html Wed, 13 May 2026 08:30:00 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Press+Releases/NEXGEL+Appoints+Dave+Hazard+as+Vice+President+of+Sales+for+BIONX+Surgical/26482335.html <p align="center"><i>Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue</i></p> <p align="justify"><b>LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- </b>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Dave Hazard as Vice President of Sales for BIONX Surgical, a division of NEXGEL. Mr. Hazard brings more than 13 years of sales leadership across orthopedics, spine, and biologics, and joins BIONX Surgical at a key http://www.streetinsider.com/Press+Releases/NEXGEL+Appoints+Dave+Hazard+as+Vice+President+of+Sales+for+BIONX+Surgical/26482335.html Wed, 13 May 2026 08:30:00 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Press+Releases/NEXGEL+Appoints+Dave+Hazard+as+Vice+President+of+Sales+for+BIONX+Surgical/26482335.html <p align="center"><i>Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue</i></p> <p align="justify"><b>LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- </b>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Dave Hazard as Vice President of Sales for BIONX Surgical, a division of NEXGEL. Mr. Hazard brings more than 13 years of sales leadership across orthopedics, spine, and biologics, and joins BIONX Surgical at a key http://www.streetinsider.com/Press+Releases/NEXGEL+Appoints+Dave+Hazard+as+Vice+President+of+Sales+for+BIONX+Surgical/26482335.html Wed, 13 May 2026 08:30:00 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768 http://www.streetinsider.com/Globe+Newswire/NEXGEL+Appoints+Dave+Hazard+as+Vice+President+of+Sales+for+BIONX+Surgical/26482335.html <p align="center"><i>Appointment Supports Commercialization of Newly Launched BIONX Surgical Division, Formed Through Transformative Acquisition Expected to Significantly Scale Revenue</i></p> <p align="justify"><b>LANGHORNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- </b>NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced the appointment of Dave Hazard as Vice President of Sales for BIONX Surgical, a division of NEXGEL. Mr. Hazard brings more than 13 years of sales leadership across orthopedics, spine, and biologics, and joins BIONX Surgical at a key http://www.streetinsider.com/Globe+Newswire/NEXGEL+Appoints+Dave+Hazard+as+Vice+President+of+Sales+for+BIONX+Surgical/26482335.html Wed, 13 May 2026 08:30:00 -0400 A.13662202 NXGL NXGLW O.00063751 O.08214768